BiotechTube
CyanVac

CyanVac

Athens, United States· Est.
cyanvacllc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

CyanVac is a clinical-stage biotech advancing a pipeline of intranasal vaccines based on its proprietary PIV5 viral vector platform. Its lead programs target COVID-19 and RSV, both in clinical trials, with preclinical work in pandemic flu, norovirus, and Lyme disease. The company's strategy focuses on generating robust mucosal immunity to potentially block infection and transmission, addressing key limitations of injectable vaccines. CyanVac operates as a private entity and appears to be pre-revenue, leveraging its platform for both proprietary programs and through its affiliate, Blue Lake Biotechnology.

Infectious DiseaseRespiratory Diseases

Technology Platform

Proprietary intranasal vaccine platform based on a modified parainfluenza virus 5 (PIV5) vector, engineered to express target antigens and designed to induce robust cellular, humoral, and mucosal immunity.

Funding History

2
Total raised:$15M
Series A$15M
GrantUndisclosed

Opportunities

The company's intranasal platform addresses large markets with unmet needs for transmission-blocking immunity, particularly in pediatric RSV and Lyme disease where no vaccines are currently available.
Needle-free administration could reduce hesitancy and enable easier distribution, creating a competitive edge in booster and pandemic preparedness markets.

Risk Factors

Clinical failure of the lead PIV5 platform would jeopardize the entire pipeline.
The company faces intense competition from large pharma in core respiratory markets and is reliant on raising significant capital to fund late-stage development as a pre-revenue private entity.

Competitive Landscape

CyanVac competes in crowded respiratory vaccine markets dominated by giants like Pfizer, Moderna, and GSK. Its differentiation hinges on mucosal immunity and intranasal delivery, competing against other intranasal candidates (e.g., Codagenix's RSV) and next-generation platforms. In Lyme and norovirus, it faces earlier-stage biotechs but with a potentially first-to-market advantage.

More companies in Biologics / Biosimilars →More companies in United States →